Armenia - engelsk - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

f. hoffmann-la roche ltd. - tocilizumab - concentrate for solution for i/v infusion - 20mg/ml

Armenia - engelsk - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

f. hoffmann-la roche ltd. - tocilizumab - concentrate for solution for i/v infusion - 20mg/ml

Israel - engelsk - Ministry of Health

roche pharmaceuticals (israel) ltd - tocilizumab - concentrate for solution for infusion - tocilizumab 20 mg/ml - tocilizumab - tocilizumab - actemra (tocilizumab), is indicated for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who had an inadequate response to one or more dmards(disease modifying anti-rheumatic drugs) or tnf antagonists or in whom dmards cannot be used. actemra can be used alone or in combination with methotrexate or other dmards. actemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. actemra is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. actemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. actemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. actemra in combination with methotrexate (mtx) in indicated for the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx.actemra is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 3 years of age and older.actemra is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.

Den europeiske union - engelsk - EMA (European Medicines Agency)

roche registration gmbh - tocilizumab - arthritis, rheumatoid; arthritis, juvenile rheumatoid; cytokine release syndrome; giant cell arteritis; covid-19 virus infection - immunosuppressants - roactemra, in combination with methotrexate (mtx), is indicated forthe treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx.the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists.in these patients, roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.roactemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate.roactemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. roactemra can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.roactemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx.  roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.roactemra is indicated for the treatment of giant cell arteritis (gca) in adult patients.roactemra, in combination with methotrexate (mtx), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx.the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists.in these patients, roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. roactemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate.roactemra is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.roactemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 2 years of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. roactemra can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.roactemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.roactemra is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older.roactemra, in combination with methotrexate (mtx), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx.the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists.in these patients, roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. roactemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate.roactemra is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.roactemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 2 years of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. roactemra can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.roactemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.roactemra is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older.

Canada - engelsk - Health Canada

hoffmann-la roche limited - tocilizumab - solution - 80mg - tocilizumab 80mg - disease-modifying antirheumatic agents

Canada - engelsk - Health Canada

hoffmann-la roche limited - tocilizumab - solution - 200mg - tocilizumab 200mg - disease-modifying antirheumatic agents

Canada - engelsk - Health Canada

hoffmann-la roche limited - tocilizumab - solution - 400mg - tocilizumab 400mg - disease-modifying antirheumatic agents

Canada - engelsk - Health Canada

hoffmann-la roche limited - tocilizumab - solution - 162mg - tocilizumab 162mg - disease-modifying antirheumatic agents

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - tocilizumab - solution for injection - 180mg/1ml

Canada - engelsk - Health Canada

hoffmann-la roche limited - tocilizumab - solution - 162mg - tocilizumab 162mg - disease-modifying antirheumatic agents